Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of an Investigational Eye Drop in Dry Eye Sufferers
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01339936 |
|
Recruitment Status :
Completed
First Posted : April 21, 2011
Results First Posted : November 28, 2013
Last Update Posted : November 28, 2013
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Dry Eye Syndrome | Device: Carboxymethylcellulose sodium, glycerin and polysorbate 80 | Phase 2 Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 40 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Basic Science |
| Study Start Date : | March 2011 |
| Actual Primary Completion Date : | August 2011 |
| Actual Study Completion Date : | May 2012 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Investigational eye drop
Formulation 1: Carboxymethylcellulose sodium, glycerin and polysorbate 80 based eye drops formulated for the relief of ocular surface irritation and symptoms of dryness
|
Device: Carboxymethylcellulose sodium, glycerin and polysorbate 80
1 drop in each eye three times a day for a period of 30 (± 4) days |
- Tear Film Evaporation Rate [ Time Frame: after 30 days of eyedrop usage ]The rate of evaporation of the tears from the ocular surface was measured. To do so the participant was required to wear a sealed goggle over the eye, which served to isolate the air surrounding the ocular surface. The temperature and humidity were measured within the sealed goggle during closed eye and open eye situations. The evaporation from the ocular surface was calculated by taking the difference between the evaporation rate of the skin taken during the closed eye measurement and the evaporation rate taken during the open eye measurement. The rate of evaporation was measured in 10^-7 g/cm^2 /s and recorded for relative humidity of 25% to 35%.
- Tear Break Up Time [ Time Frame: after 30 days of eyedrop usage ]The tear film break-up-time (BUT) is the time elapsed between eye opening after a blink, and the appearance of the first dark spot within the tear film when observed with a wide diffuse light source of the Tearscope. This measurement is indicative of the tear film stability. Three independent measurements were recorded in each case and the median value over the three measurements calculated. The latter value constituted the secondary endpoint used in the analysis.
- Ocular Surface Disease Index Score [ Time Frame: after 30 days of eye drop usage ]
The OSDI is a 12-item patient-reported outcomes questionnaire designed to assess the range of ocular surface symptoms, their severity, and their impact on the patient's ability to function.
The OSDI items are scored on a 0 to 4 Likert-type scale, where 0 = None of the time, 1 = Some of the time, 2 = Half of the time, 3 = Most of the time, and 4 = All of the time. Using individual item responses, an overall OSDI score is calculated. The overall OSDI score ranges from 0 to 100, where a score of 100 corresponds to complete disability while a score of 0 corresponds to no disability.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Mild or greater dry eye symptoms.
- Evidence of evaporative dry eye
Exclusion Criteria:
- Known allergy or sensitivity to the study product(s) or its components
- Current contact lens wearer
- Systemic or ocular allergies
- Use of systemic medication which might have ocular side effects.
- Any ocular infection.
- Use of ocular medication.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01339936
| United Kingdom | |
| OTG Research & Consultancy | |
| London, England, United Kingdom, SW1E 6AU | |
| Responsible Party: | Optometric Technology Group Ltd |
| ClinicalTrials.gov Identifier: | NCT01339936 |
| Other Study ID Numbers: |
AG9965-005 ID 10-12 |
| First Posted: | April 21, 2011 Key Record Dates |
| Results First Posted: | November 28, 2013 |
| Last Update Posted: | November 28, 2013 |
| Last Verified: | September 2013 |
|
Dry Eye Syndromes Keratoconjunctivitis Sicca Lacrimal Apparatus Diseases Eye Diseases Keratoconjunctivitis Conjunctivitis Conjunctival Diseases Keratitis |
Corneal Diseases Carboxymethylcellulose Sodium Glycerol Laxatives Gastrointestinal Agents Cryoprotective Agents Protective Agents Physiological Effects of Drugs |

